In almost every other sector of the economy, knowing the price of a product is a basic right of the consumer. In healthcare, however, the final cost of care remains one of the industry’s best-kept secrets. While proponents argue that price transparency is essential for a competitive market, the reality is more complex: opacity is not just a byproduct of bureaucracy, but a deliberate business strategy designed to maximize profits for insurers, pharmacy benefit managers (PBMs), and pharmaceutical manufacturers.
The Myth of Consumer Choice
The primary argument against price transparency often hinges on the idea that patients cannot use this information effectively. Unlike buying an airline ticket or ordering from a restaurant menu, healthcare decisions are rarely planned or comparable. Patients rarely know in advance which tests, procedures, or medications they will need, particularly in emergencies or complex chronic conditions.
“Healthcare is the only place where you can’t see your prices,” noted Health and Human Services Secretary Robert F. Kennedy Jr., highlighting the stark contrast between healthcare and other consumer markets.
Because patients lack the ability to “shop around” for immediate care, industry stakeholders argue that forcing price disclosure offers little tangible benefit to the end-user. However, this perspective overlooks the broader economic impact. While individual patients may not use price tags to choose a hospital, employers and group health plans do. For these bulk purchasers, transparency is a powerful tool to negotiate better rates, select efficient provider networks, and manage the rising costs of employee insurance benefits.
How Secrecy Drives Profit
The resistance to transparency stems from a business model built on asymmetric information and price discrimination. In a transparent market, prices tend to converge toward a fair value. In healthcare, stakeholders rely on keeping net prices proprietary to charge different prices to different buyers.
This dynamic is particularly evident in the pharmaceutical supply chain:
- Secret Rebates: Drug manufacturers often negotiate high rebates with Pharmacy Benefit Managers (PBMs) in exchange for favorable placement on insurance formularies. These net prices are hidden from the public.
- The Pass-Through Problem: PBMs argue that disclosing these deals would force them to share rebates with all clients, discouraging manufacturers from offering discounts in the first place. However, these rebates are frequently not passed directly to patients at the pharmacy counter. Instead, they often remain as profit for the PBM or are used to lower premiums in ways that are difficult for patients to trace.
- Spread Pricing: Intermediaries, including hospitals and contract pharmacies, often exploit “spread margins.” They purchase drugs at heavily discounted rates but are reimbursed at higher rates, pocketing the difference. Opacity protects these excess profits.
By fragmenting the market—separating Medicare, Medicaid, and commercial insurers by age, income, and status—companies can tailor prices to each segment without public scrutiny. This allows them to maximize revenue from each distinct group while preventing cross-market price comparisons that would drive costs down.
The Push for Accountability
Lawmakers are increasingly recognizing that this lack of transparency burdens the entire system. Representative John James (R-MI), lead sponsor of the bipartisan “Patients Deserve Price Tags Act,” has criticized the industry for hiding prices, noting that secrecy is typically used only when entities have something to conceal.
Recent legislative and regulatory actions aim to pierce this veil:
- Federal Law: President Trump signed legislation requiring PBMs to disclose direct and indirect compensation, as well as gross and net drug spending for companies with at least 100 employees. These mandates, including reporting on drug acquisition costs and pharmacy reimbursements, are set to take effect in January 2029.
- Department of Labor Rule: A proposed rule targets the self-insured plan market, aiming to accelerate transparency by July of this year. It requires similar disclosures regarding drug pricing and PBM practices.
These measures seek to establish government-published benchmarks based on actual transaction prices, creating a baseline for fair competition.
The Battle for the Status Quo
The healthcare industry’s opposition to these changes is fierce. Stakeholders with vested interests in the current opaque system are lobbying aggressively and preparing for legal challenges. They view confidentiality as a “third rail” issue—essential to their profitability and market segmentation.
However, early evidence from states like Florida and New York suggests that public disclosure of competitive pricing can lead to modest reductions in healthcare costs. As policymakers move from theoretical debates to concrete enforcement, the industry faces a pivotal choice: adapt to a more open market or continue fighting a trend that could fundamentally reshape how healthcare is priced and delivered.
Ultimately, while price transparency may not solve every healthcare cost issue, it removes the blindfold from the market, allowing purchasers and policymakers to make informed decisions rather than relying on hidden margins and secret deals.
